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In the past decade, the number of drug and bio-
logical product submissions to the United States
Food and Drug Administration (FDA) has been
slowly declining, while biomedical research spend-
ing has increased. Investment in the discovery
phase per successful drug was the same between
1995–2000 and 2000–2002. On the other hand,
investment in critical path initiatives almost dou-
bled in 2000–2002 compared with 1995–2000.
The increased focus on biomedical research allows
for possible discovery of innovative products that
may provide prevention, treatment and cure of
serious diseases that affect contemporary society.
Scientific knowledge is advancing, yet using 
this knowledge to help society is at a standstill.
Increased biomedical spending, combined with
fewer drug submissions, leads to critical paths be-
coming very expensive and the cost of success of a
compound is greatly escalated.
Possible reasons and explanations for this
phenomenon of decreased success are that the
tools and concepts of the last century are being
used to evaluate this century’s drug candidates.
This indicates that recently discovered innovative
drugs are still evaluated by ordinary endpoints,
which cannot measure the proper profile of the
innovative drugs. In a 2004 FDA and industry
workshop, Dr Janet Woodcock noted that “cur-
rently, one out of every two phase III trials fails”,
which means that the success rate of clinical trials is
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decreasing to <50% in the United States. To com-
bat this decrease, FDA’s Critical Path Initiative (CPI)
believes that it is necessary to “develop new, publicly
available scientific and technical tools—including
assays, standards, computer modeling techniques,
biomarkers, and clinical trial endpoints—that make
the development process itself more efficient and
effective and more likely to result in safe products
that benefit patients”.1 Therefore, a new approach
to develop and evaluate the efficiency and effec-
tiveness of promising innovative drug candidates is
required.
A similar situation can be seen in Japan: the
number of domestic clinical trials is diminishing,
and the cost of conducting a trial is rising. For ex-
ample, in 1992, only 18.3% of compounds were
first developed outside of Japan by Japanese do-
mestic companies, but in 2000, 43.2% of the com-
pounds were developed outside of Japan. It is also
known that the speed of conducting clinical trials
in Japan is very slow. The three factors of high
cost, slow speed, and foreign conduct of clinical
trials by Japanese domestic companies comprises
the phenomenon called “hollowing out of clinical
trials” in Japan. To prevent further decrease in the
number of clinical trials in Japan, we need a new
approach to clinical research. A possible solution
is an adaptive design in research and development,
which borrows accumulated clinical information,
thus modifying the trial design in terms of re-
quired sample size and/or dropping one or two
arms of a phase III trial, for confirmation of the
efficacy/safety of the treatment being tested.
Concept of Integrative Celerity 
Research in Japan
Integrative celerity research (ICR), proposed by
Imura, aims to combine both critical path re-
search and translational research.2 Figure 1 shows
the concept of ICR. In Japan, translational research
activity has been growing, and the results of the
research have been published in leading journals
such as Science. Unfortunately, clinical research ac-
tivity in Japan has not increased and is not recog-
nized when compared with translational research.
Therefore, the purpose of ICR is to unite the
achievements of basic science with the activity of
clinical research. Not only does ICR aim to com-
bine critical and translational research, new per-
spectives on clinical research can be formulated by
the introduction of bridging studies and the par-
ticipation of Japan in Asian and global studies.
In 1998, the E5 guideline, which allows extrapola-
tion of the results of foreign clinical trials to Japan
for the approval of new drugs, was adopted. More
than 40 compounds have been approved through
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Figure 1. Concept of integrative celerity research in Japan.
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extrapolation of foreign clinical trial results by
conducting a small study, known as a bridging
study.3,4 Bridging studies provide the necessary in-
formation regarding differences in ethnic, intrinsic
and extrinsic factors among foreign and Japanese
subjects. We can apply the concept of bridging
studies to simultaneous ongoing global studies
with further extensive experience. The key factor
in both bridging and global studies is to recognize
an appropriate dosage in Japanese patients.
Adaptive Design in Japan
Currently, adaptive design in the US and EU
combine phase II and III with a single assessment
in each phase. In order for Japan to participate in
global studies, Japan will also have to apply the
concept of adaptive design to combine phase II
and III. Since dosage determination is a key, ada-
ptive design must be modified. The modified
adaptive design is much more complex than the
designs used in the US and EU. Figure 2 summa-
rizes the main idea of adaptive design in Japan.
In phase II trials, a new dosage such as a low-low
dosage may be introduced to investigate intrinsic
factors in Japanese patients. As part of translational
research in Japanese trials, a futility assessment
using surrogate/biomarkers, computer modeling
and pharmacogenomics is needed as a primary
assessment in phase II trials to determine the
dose–response curve. Thus, in the Japanese design,
two assessments in phase II will be required. The
second assessment of phase II will investigate the
probability of success by modeling, validation of
surrogate/biomarkers, and patient variability
through pharmacogenomic information.
This approach raises statistical concerns and
issues. The small sample size in Japanese trials
compared with that in other countries raises the
concern of evaluating efficacy and producing ad-
equate power in the trial. To combat this concern,
the concept in bridging studies of applying simi-
larity of efficacy among countries in the same
clinical trial may be used. Determination of an
appropriate dosage range for the Japanese popu-
lation is another issue that has to be addressed.
An additional dosage must be introduced as must
the application of the concept of similarity to de-
termine whether or not the new dosage is appro-
priate for a Japanese population. To implement the
suggested adaptive design in Japan, there is a need
for the accumulation of clinical data such as effi-
cacy and dosage through an electronic data cap-
ture (EDC) system. Currently, there are two types
of good clinical practice (GCP) in Japan, J-GCP
and ICH-GCP.5,6 The different GCPs prevent im-
plementing an EDC system in Japan. To conduct
and evaluate the clinical data results in a timely
fashion, professional clinical specialists in regula-
tory agencies, academia and industry are needed.
Training these professionals demands adequate
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Figure 2. Application of possible approach.
educational programs, not only for biostatisticians,
but also for clinicians.
Construction of a Safety Network
System
Application of this new approach causes major
concerns regarding safety, because the number of
exposed patients will decrease through possible
extrapolation of foreign clinical data for evaluation
of efficacy. A large database to detect severe and
regionally oriented adverse events will be required.
A possible solution is to build a strong safety net-
work between hospitals to construct and evalu-
ate the data from all patients who are prescribed
the drug after approval. The Ministry of Health,
Labor and Welfare has established a research grant
to focus on implementing a network between
hospitals. This system aims to develop a strong
and validated EDC system to collect clinical data,
monitor patients, and detect unexpected adverse
events, as well as building a database of patient
background details for signal detection and
pharmacoepidemiology.
Overall, there are two main steps in creating an
efficient and safe networking system in Japan.
Figure 3 shows the construction of a network sys-
tem in Japan. A safety data capturing system within
a medical facility must be developed. Within each
medical facility, unification of patient medical
records regarding patient background, dosage, ef-
ficacy and safety of the patients is essential. In most
cases, medical records exist in several different de-
partments of the medical facility. Data about each
patient must be unified within each medical facil-
ity, followed by the unification of the databases
from all the medical facilities into one main data
center. Compiling patient data into one center al-
lows for a simultaneous monitoring system, which
will help to detect unexpected adverse events and
analyze safety profiles according to actual drug
dosage and duration of treatment.
Similar to the FDA’s CPI, Japan’s mission is to
develop better drugs more efficiently, with new
drug development methodologies, by participating
mainly in global/Asian studies. Although devel-
oping better drugs in a time-efficient manner is
important, patient safety must be a priority. The
importance of pharmacovigilance by monitoring
patients, developing a patient database through
a safety network, and a unified EDC system be-
tween Japan and other Asian countries are all fac-
tors that will help maintain patient safety. Finally,
team work between clinical trial specialists, com-
puter scientists, medical doctors, and statisticians
is important for the success of adaptive design in
Japanese research and development.
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Figure 3. Construction of a safety network system in Japan.
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